Comparative Pharmacology
Head-to-head clinical analysis: RITODRINE HCL versus RITODRINE HYDROCHLORIDE IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RITODRINE HCL versus RITODRINE HYDROCHLORIDE IN DEXTROSE 5 IN PLASTIC CONTAINER.
RITODRINE HCL vs RITODRINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-2 adrenergic receptor agonist; stimulates beta-2 receptors in uterine smooth muscle, causing relaxation and inhibiting uterine contractions. Also has some beta-1 activity at higher doses.
Ritodrine is a beta-2 adrenergic receptor agonist that stimulates adenylate cyclase, increasing cyclic AMP levels, leading to relaxation of uterine smooth muscle. It also has some beta-1 activity.
10 mg orally every 2 hours for preterm labor; initially 50-100 mcg/min IV, titrated to response, maximum 350 mcg/min.
Intravenous infusion: initial rate 0.05 mg/min (50 mcg/min), increase by 0.05 mg/min every 10 minutes until effective or maternal heart rate >130 bpm; maximum rate 0.35 mg/min (350 mcg/min). Maintenance: continue at lowest effective rate for 12-48 hours after contractions cease.
None Documented
None Documented
Terminal elimination half-life: 15-17 hours in pregnant women; 2-4 hours in non-pregnant adults. Context: Half-life prolonged in pregnancy due to increased Vd and decreased clearance.
Terminal elimination half-life: 15-26 hours (mean 20 hours) in adults; prolonged in renal impairment.
Renal: 70-90% as unchanged drug and metabolites. Biliary/fecal: 10-30%.
Renal: >90% as unchanged drug and metabolites; biliary/fecal: minimal (<5%).
Category C
Category C
Tocolytic Agent
Tocolytic Agent